SVA - Sinovac Biotech Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.85
-0.03 (-0.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.88
Open7.82
Bid7.02 x 500
Ask8.18 x 6200
Day's Range7.60 - 7.86
52 Week Range4.60 - 8.75
Volume24,183
Avg. Volume62,296
Market Cap447.602M
Beta0.21
PE Ratio (TTM)24.15
EPS (TTM)0.32
Earnings DateJun 1, 2017 - Jun 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Sinovac Announces Preliminary Results of Phase III Trial on sIPV

    BEIJING, April 19, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Biotech Co., Ltd. ("Sinovac Beijing") on the unblinding conference held on April 19, 2018. The preliminary results of the trial after unblinding show the seroconversion rate of poliovirus type II is superior to the control vaccine and seroconversion rates of the other two types of poliovirus are non-inferior to the control vaccine.

  • PR Newswire2 days ago

    Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.

    - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Company and ...

  • 10 Bulletproof Blue-Chip Growth Stocks to Invest In
    InvestorPlace4 days ago

    10 Bulletproof Blue-Chip Growth Stocks to Invest In

    While traditional blue-chip stocks are good choices for the volatility in the market, another good strategy is to grab some blue-chip growth stocks to take advantage of the upside move. Bear in mind, these are small- to mid-cap stocks, so don’t chase them. Lumentum Holdings Inc (NASDAQ:LITE) is one of the biggest-cap stocks in this list, with a $4 billion market cap.

  • 10 Healthcare Stocks to Stave Off the Market Flu
    InvestorPlace14 days ago

    10 Healthcare Stocks to Stave Off the Market Flu

    While the markets run up and down because tech stocks are doing one thing or another, or retailers struggle to improve same-store sales, there isn’t much debate about the future of the healthcare sector.Source: Shutterstock

  • Why Sinovac Biotech Ltd’s (NASDAQ:SVA) ROE Of 18.01% Does Not Tell The Whole Story
    Simply Wall St.21 days ago

    Why Sinovac Biotech Ltd’s (NASDAQ:SVA) ROE Of 18.01% Does Not Tell The Whole Story

    Sinovac Biotech Ltd (NASDAQ:SVA) generated a below-average return on equity of 18.01% in the past 12 months, while its industry returned 18.11%. An investor may attribute an inferior ROE toRead More...

  • PR Newswire24 days ago

    Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction

    BEIJING, March 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (SVA), a leading provider of biopharmaceutical products in China, today announced that on March 26, 2018, it entered into Amendment No. 1 to the Amalgamation Agreement (the "Amendment") to amend the Amalgamation Agreement, dated as of June 26, 2017 (the "Amalgamation Agreement"), among the Company, Sinovac (Cayman) Limited ("Parent") and Sinovac Amalgamation Sub Limited ("Amalgamation Sub"), a wholly-owned subsidiary of Parent. Under the terms of the Amalgamation Agreement, the Amalgamation Agreement may be terminated by the Company or Parent if the amalgamation of Amalgamation Sub with and into the Company (the "Amalgamation") has not occurred on or before March 26, 2018 (the "Termination Date"). The Amendment extends the Termination Date to April 26, 2018.

  • PR Newswirelast month

    Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties

    BEIJING, March 15, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (SVA), a leading provider of biopharmaceutical products in China, today responded to public statements made by other parties falsely claiming to control the Company, including a press release falsely purporting to come from Sinovac itself. The Company emphasized that third parties, including the dissident shareholders who sought to disrupt the election of directors at the AGM  do not have the authority to determine or announce the results of Sinovac's AGM, comment on the Company's governance or speak on behalf of the Company.

  • What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like?
    Simply Wall St.last month

    What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like?

    I am going to take a deep dive into Sinovac Biotech Ltd’s (NASDAQ:SVA) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • PR Newswirelast month

    Sinovac Amends Shareholder Rights Plan

    BEIJING , March 6, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire2 months ago

    Sinovac Announces Enhancement of Corporate Governance and Management of China Operating Entity

    BEIJING , March 5, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today ...

  • PR Newswire2 months ago

    Sinovac Announces Re-Election of All Directors at Annual General Meeting

    BEIJING, March 5, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced several important developments, including the re-election of its incumbent directors at its Annual General Meeting of Shareholders (AGM), which was held on February 6, 2018, and the filing of legal actions in the Delaware Court of Chancery and in the United States District Court for Massachusetts related to actions taken by certain dissident shareholders.

  • PR Newswire2 months ago

    Sinovac Provides Update on Going Private Transaction

    BEIJING, Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that, in connection with its previously announced going private transaction, the Company has filed a going-private transaction statement on Schedule 13E-3 (as amended, the "Going-Private Statement") with the United States Securities and Exchange Commission (the "SEC"). Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement (the "Preliminary Proxy Statement"). The Company expects to file an amended Going-Private Statement, including a definitive proxy statement (which will be substantially in the same form as the Preliminary Proxy Statement and used in connection with a special meeting of shareholders) as an exhibit, with the SEC in due course.

  • PR Newswire2 months ago

    Sinovac Holds 2017 Annual General Meeting of Shareholders

    BEIJING , Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today that ...

  • What You Must Know About Sinovac Biotech Ltd’s (NASDAQ:SVA) Risks
    Simply Wall St.3 months ago

    What You Must Know About Sinovac Biotech Ltd’s (NASDAQ:SVA) Risks

    If you are looking to invest in Sinovac Biotech Ltd’s (NASDAQ:SVA), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • PR Newswire4 months ago

    Sinovac Schedules 2017 Annual Meeting of Shareholders

    BEIJING, Dec. 29, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2017 Annual Meeting of Shareholders on Tuesday, February 6, 2018 at 9:00 a.m. Beijing Time. All shareholders of record as of December 26, 2017 will be eligible to vote and are invited to attend.

  • Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) Because Of Its PE Ratio?
    Simply Wall St.4 months ago

    Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) Because Of Its PE Ratio?

    Sinovac Biotech Ltd (NASDAQ:SVA) is currently trading at a trailing P/E of 24.3x, which is lower than the industry average of 29.5x. Although some investors may jump to the conclusionRead More...

  • PR Newswire4 months ago

    Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization

    BEIJING, Dec. 22, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that it has received a positive decision from the World Health Organization ("WHO") on the acceptability, in principle, of its Healive, a hepatitis A vaccine product, for purchase by United Nations ("UN") agencies. The Company's Healive product was assessed according to the WHO Prequalification Procedure. Mr. Weidong Yin, Chairman, President and CEO of the Company, commented that "I am very pleased that Healive has passed the assessment under WHO Prequalification procedures.

  • ACCESSWIRE4 months ago

    Wired News – Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300

    Stock Monitor: Sinovac Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Onconova Therapeutics, Inc. (NASDAQ: ONTX ) ...

  • ACCESSWIRE4 months ago

    Blog Exposure - BeiGene Announced Initiation of Pivotal Trial of PARP Inhibitor Pamiparib in Chinese Patients with Ovarian Cancer

    Stock Monitor: Sinovac Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 20, 2017 / Active-Investors issued a free report on BeiGene, Ltd. (NASDAQ: BGNE ), which is readily accessible ...

  • PR Newswire5 months ago

    Sinovac Biotech Cures Nasdaq Filing Deficiency

    BEIJING , Dec. 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China , announced today that ...

  • PR Newswire5 months ago

    Sinovac Reports Unaudited First Half of 2017 Financial Results

    BEIJING , Dec. 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today that ...

  • PR Newswire5 months ago

    Sinovac Biotech Announces Update on Nasdaq Matters

    BEIJING , Nov. 30, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China , announced today ...

  • Associated Press5 months ago

    Sinovac posts 4Q profit

    On a per-share basis, the Beijing-based company said it had profit of 8 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 11 cents per share. The biopharmaceutical company ...

  • PR Newswire5 months ago

    Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results

    BEIJING , Nov. 22, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the " C ompan y" ), a leading provider of biopharmaceutical products in China , announced today ...

  • Is Sinovac Biotech Ltd’s (SVA) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.5 months ago

    Is Sinovac Biotech Ltd’s (SVA) Balance Sheet Strong Enough To Weather A Storm?

    Sinovac Biotech Ltd (NASDAQ:SVA) is a small-cap stock with a market capitalization of USD $409.97M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...